WP
PTGX icon

Woodline Partners’s Protagonist Therapeutics PTGX Stock Holding History

Woodline Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$149M Buy
1,414,173
+5,401
+0.4% +$478K 0.56% 24
2025
Q4 		$123M Sell
1,408,772
-29,475
-2% -$2.41M 0.48% 29
2025
Q3 		$95.5M Buy
1,438,247
+491,363
+52% +$27.9M 0.45% 44
2025
Q2 		$52.3M Buy
946,884
+49,185
+5% +$2.36M 0.28% 88
2025
Q1 		$43.4M Buy
897,699
+315,372
+54% +$13.2M 0.28% 103
2024
Q4 		$22.5M Buy
582,327
+115,809
+25% +$5.05M 0.15% 195
2024
Q3 		$21M Sell
466,518
-355,655
-43% -$14.4M 0.18% 186
2024
Q2 		$28.5M Buy
822,173
+185,217
+29% +$5.42M 0.27% 115
2024
Q1 		$18.4M Buy
+636,956
New +$17.3M 0.17% 183
2023
Q3 		– Sell
-427,264
Closed -$11.8M – 713
2023
Q2 		$11.8M Sell
427,264
-191,351
-31% -$4.79M 0.14% 185
2023
Q1 		$14.2M Buy
618,615
+106,475
+21% +$1.79M 0.19% 150
2022
Q4 		$5.59M Buy
+512,140
New +$4.32M 0.07% 295
2022
Q3 		– Sell
-388,637
Closed -$3.07M – 809
2022
Q2 		$3.07M Sell
388,637
-200,057
-34% -$2.42M 0.05% 327
2022
Q1 		$13.9M Buy
588,694
+95,707
+19% +$2.7M 0.23% 135
2021
Q4 		$16.9M Buy
+492,987
New +$15.6M 0.24% 121

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Woodline Partners's PTGX Position: Q1 2026 in Review

Woodline Partners increased its Protagonist Therapeutics (PTGX) stake by 0.38% in Q1 2026, buying an estimated $478K and bringing the position to 1,414,173 shares worth $149M. The position accounts for 0.56% of the portfolio, ranked #24.

Woodline Partners first reported a position in PTGX in Q4 2021 and has held it in 15 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Woodline Partners held 1,414,173 shares of Protagonist Therapeutics worth $149M as of Q1 2026.
  • Woodline Partners bought 5,401 Protagonist Therapeutics shares in Q1 2026, an estimated $478K.
  • Protagonist Therapeutics made up 0.56% of Woodline Partners's portfolio in Q1 2026, its #24 holding.
  • Woodline Partners first reported a position in Protagonist Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.